États-Unis · Plateformes & données · MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Publié par MarketBeat · États-Unis il y a 42 min

Morgan Stanley increased their price objective on Kymera Therapeutics from $135.00 to $146.00 and gave the stock an "overweight" rating in a research report on Tuesday.

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

À lire aussi

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Partager

À lire aussi

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live